Related Experiment Video
Updated: Jun 16, 2026
06:10
An Ex Vivo Choroid Sprouting Assay of Ocular Microvascular Angiogenesis
Published on: August 6, 2020
Mediators of ocular angiogenesis.
Yureeda Qazi1, Surekha Maddula, Balamurali K Ambati
1Department of Ophthalmology, John Moran Eye Center, University of Utah, Salt Lake City, UT-84132, USA.
Journal of Genetics
|January 22, 2010
Summary
This review explores molecular factors driving pathological angiogenesis in eye diseases like diabetic retinopathy and macular degeneration. It highlights new therapeutic targets for preventing vision loss by controlling blood vessel formation.
Area of Science:
- Ophthalmology
- Vascular Biology
- Molecular Medicine
Background:
- Pathologic new blood vessel formation (angiogenesis) in the eye causes severe vision loss.
- Key ocular diseases involve abnormal angiogenesis, including corneal angiogenesis, proliferative diabetic retinopathy, exudative macular degeneration, and retinopathy of prematurity.
Purpose of the Study:
- To review the roles of pro-angiogenic and anti-angiogenic molecular factors in major ocular angiogenesis diseases.
- To identify and highlight novel therapeutic targets discovered in the last decade for treating these conditions.
Main Methods:
- Systematic literature review of studies on molecular players in ocular angiogenesis.
- Analysis of pro-angiogenic and anti-angiogenic mechanisms in specific eye diseases.
Main Results:
- Identified critical molecular mediators that promote or inhibit blood vessel growth in the eye.
- Highlighted emerging therapeutic targets with potential to modulate pathologic angiogenesis.
Conclusions:
- Understanding the molecular basis of angiogenesis is crucial for developing effective treatments for vision-threatening eye diseases.
- Novel molecular targets offer promising avenues for future therapeutic interventions to preserve sight.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...